Natco Pharma Ltd
NSE:NATCOPHARM
Intrinsic Value
NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. [ Read More ]
The intrinsic value of one NATCOPHARM stock under the Base Case scenario is 1 304.96 INR. Compared to the current market price of 974 INR, Natco Pharma Ltd is Undervalued by 25%.
Valuation Backtest
Natco Pharma Ltd
Run backtest to discover the historical profit from buying and selling NATCOPHARM stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Natco Pharma Ltd
Current Assets | 33.5B |
Cash & Short-Term Investments | 12.2B |
Receivables | 11.3B |
Other Current Assets | 10.1B |
Non-Current Assets | 29B |
Long-Term Investments | 2.6B |
PP&E | 23.5B |
Intangibles | 2B |
Other Non-Current Assets | 978m |
Current Liabilities | 8.8B |
Accounts Payable | 3.7B |
Short-Term Debt | 2.4B |
Other Current Liabilities | 2.7B |
Non-Current Liabilities | 822m |
Long-Term Debt | 62m |
Other Non-Current Liabilities | 760m |
Earnings Waterfall
Natco Pharma Ltd
Revenue
|
38.3B
INR
|
Cost of Revenue
|
-8.3B
INR
|
Gross Profit
|
30B
INR
|
Operating Expenses
|
-15.8B
INR
|
Operating Income
|
14.2B
INR
|
Other Expenses
|
-1.4B
INR
|
Net Income
|
12.8B
INR
|
Free Cash Flow Analysis
Natco Pharma Ltd
NATCOPHARM Profitability Score
Profitability Due Diligence
Natco Pharma Ltd's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
Score
Natco Pharma Ltd's profitability score is 68/100. The higher the profitability score, the more profitable the company is.
NATCOPHARM Solvency Score
Solvency Due Diligence
Natco Pharma Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Natco Pharma Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NATCOPHARM Price Targets Summary
Natco Pharma Ltd
According to Wall Street analysts, the average 1-year price target for NATCOPHARM is 918.55 INR with a low forecast of 626.2 INR and a high forecast of 1 260 INR.
Shareholder Return
NATCOPHARM Price
Natco Pharma Ltd
Average Annual Return | 7.71% |
Standard Deviation of Annual Returns | 40.33% |
Max Drawdown | -54% |
Market Capitalization | 174.5B INR |
Shares Outstanding | 179 040 400 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the development, manufacture and commercialization of complex pharmaceuticals catering to niche therapeutic areas. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.
Contact
IPO
Employees
Officers
The intrinsic value of one NATCOPHARM stock under the Base Case scenario is 1 304.96 INR.
Compared to the current market price of 974 INR, Natco Pharma Ltd is Undervalued by 25%.